GlaxoSmithKline has become the latest drugmaker to announce a series of measures designed to increase transparency about the grants it gives out.

The firm says that from the beginning of next February, it will “proactively report educational and charitable grants provided to US health-related organisations”. The report will be updated on a quarterly basis and will include grants provided to hospitals, teaching institutions, “managed care organisations,
professional associations, patient advocacy groups, and continuing medical education companies”.

Chris Viehbacher, president of GSK’s North American pharmaceuticals operations, said that the firm sponsors a range of third-party independent educational programmes “to increase awareness and knowledge about health-related issues.” Now, “by publishing information about our grants, we transparently identify the support we offer for independent and quality education to improve the delivery of health care for patients,” he added.

GSK’s decision comes after fellow pharma giant Pfizer said, in May and a year after Eli Lilly, that it will post a list of grants and charitable contributions as part of “an ongoing drive throughout the company to increase transparency”.

GSK to pay $48.5 million milestone to Genmab
Meantime GSK partner Genmab says it has reached the fifth milestone for HuMax-CD20 (ofatumumab) under the terms of its collaboration with the UK drugmaker. A payment of around DKK 232.7 million Danish kroner ($48.5 million) was triggered by the achievement of positive results in a Phase III study of ofatumumab in refractory chronic lymphocytic leukaemia, bringing the total the Denmark-based firm has received thus far to $110 million.